LEADER 01028nam a2200313 i 4500 001 991000982179707536 005 20020507104721.0 008 970307s1964 us ||| | eng 035 $ab10157013-39ule_inst 035 $aLE00640154$9ExL 040 $aDip.to Fisica$bita 084 $a53.1.4 084 $a53.3.13 084 $a53.5 084 $a53.8 084 $a530.12 084 $aQC174.5 100 1 $aTinkham, Michael$09018 245 10$aGroup theory and quantum mechanics /$cMichael Tinkham 260 $aNew York :$bMcGraw-Hill Book Co.,$c1964 300 $axii, 340 p. :$bill. ;$c23 cm. 490 0 $aInternational series in pure and applied physics 650 4$aGroup theory 907 $a.b10157013$b17-02-17$c27-06-02 912 $a991000982179707536 945 $aLE006 53.3.13 TIN$g1$i2006000075756$lle006$o-$pE0.00$q-$rl$s- $t0$u4$v0$w4$x0$y.i10189889$z27-06-02 996 $aGroup theory and quantum mechanics$9187242 997 $aUNISALENTO 998 $ale006$b01-01-97$cm$da $e-$feng$gus $h0$i1 LEADER 02227nam 22004931 450 001 9910794982703321 005 20190531095102.3 010 $a93-5328-003-6 010 $a93-86446-77-4 010 $a93-86446-78-2 035 $a(CKB)4340000000195867 035 $a(MiAaPQ)EBC4987846 035 $a(Au-PeEL)EBL4987846 035 $a(CaPaEBR)ebr11430023 035 $a(CaONFJC)MIL1031927 035 $a(OCoLC)993033157 035 $a(CaToSAGE)SAGE000006944 035 $a(EXLCZ)994340000000195867 100 $a20190531e20172017 fy| 0 101 0 $aeng 135 $aur||||||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aWeaving analytics for effective decision making /$fArindam Banerjee, Tanushri Banerjee 205 1$a1st edition. 210 1$aLos Angeles, CA :$cSAGE Publications, Inc.,$d2017. 215 $a1 online resource (164 pages) $cillustrations 311 $a93-86446-76-6 330 8 $aWeaving Analytics for Effective Decision Making helps managers unleash the power of analytics. It provides a roadmap for implementing analytics and securing a high return on investment for the organization. The book is meant primarily for decision makers, business leaders and business problem solvers who are engaged in decision-making roles in organizations. Several books have established the need for analytics in decision making; this book moves one step ahead and explains how managers can maximize the benefits of analytics in organizations. It spells out the sequence business managers should adopt towards building business intelligence-driven organizations. 606 $aIndustrial management$xDecision making$xData processing 606 $aBusiness$xDecision making$xData processing 615 0$aIndustrial management$xDecision making$xData processing. 615 0$aBusiness$xDecision making$xData processing. 676 $a658.4032 700 $aBanerjee$b Arindam$f1965-$01518357 702 $aBanerjee$b Tanushri 801 0$bCaToSAGE 801 1$bCaToSAGE 801 2$bUtOrBLW 906 $aBOOK 912 $a9910794982703321 996 $aWeaving analytics for effective decision making$93755897 997 $aUNINA LEADER 03233nam 2201009z- 450 001 9910576883303321 005 20220621 035 $a(CKB)5720000000008342 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/84479 035 $a(oapen)doab84479 035 $a(EXLCZ)995720000000008342 100 $a20202206d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aPersonalized Medicine in Epidemics 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (160 p.) 311 08$a3-0365-4208-6 311 08$a3-0365-4207-8 330 $aThis reprint contains 11 chapters on a wide range of subjects related to the impacts of different types of epidemics on our ability to practice personalized medicine. Together, these chapters provide a broad overview with many different examples of epidemics. The personalization of medicine is present both despite and because of epidemics. Many more examples are possible, but this reprint offers a primary overview emphasizing the widely spread relevance of the topic. 606 $aMedicine and Nursing$2bicssc 606 $aPharmacology$2bicssc 610 $aabdominal adiposity 610 $aadolescents 610 $aaging 610 $abiomarkers 610 $ablood pressure 610 $aboys 610 $acaries 610 $achildren 610 $achronic kidney disease 610 $acluster analyses 610 $acommunity 610 $aCovid-19 610 $aCOVID-19 610 $adental treatment 610 $adiabetes mellitus 610 $adiabetic ketoacidosis 610 $adiffuse large B-cell lymphoma 610 $adisability 610 $aearly diagnosis 610 $aeducation 610 $aelderly 610 $aepidemics 610 $aepidemiology 610 $afibrosis 610 $ahepatitis C virus 610 $ahost genetics 610 $ahypertension and type 2 diabetes mellitus comorbidity 610 $ahyperuricemia 610 $aIgG 610 $aJordan 610 $aliver toxicity 610 $alung cancer screening 610 $amicro- and macrovascular disease 610 $aN-glycosylation 610 $an/a 610 $aobesity 610 $aoral health 610 $aperformance status 610 $apersonalized medicine 610 $aprecision medicine 610 $apulmonary function 610 $aquality of life 610 $arenal progression 610 $arespiratory symptoms 610 $arisk factors 610 $aSARS CoV2 610 $asex 610 $asmoking 610 $asurvival 610 $atongue pressure 610 $atuberculosis 610 $atype 1 diabetes mellitus 610 $aviral genome 610 $awillingness to screen 615 7$aMedicine and Nursing 615 7$aPharmacology 700 $aMiddelburg$b Rutger A$4edt$01307636 702 $aMiddelburg$b Rutger A$4oth 906 $aBOOK 912 $a9910576883303321 996 $aPersonalized Medicine in Epidemics$93028885 997 $aUNINA